Grepafloxacin
From Wikipedia, the free encyclopedia
|
Grepafloxacin
|
|
| Systematic (IUPAC) name | |
| 1-cyclopropyl-6-fluoro-5-methyl-7-(3-methylpiperazin-1-yl)- 4-oxo-quinoline- 3-carboxylic acid | |
| Identifiers | |
| CAS number | |
| ATC code | J01 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C19H22FN3O3 |
| Mol. mass | 359.395 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Protein binding | 50% |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Grepafloxacin hydrochloride (Raxar, Glaxo Wellcome) is an oral broad-spectrum quinoline antibacterial agent used to treat bacterial infections. Grepafloxacin was withdrawn in the United States owing to its side effect of lengthening the QT interval on the electrocardiogram, leading to cardiac events and sudden death.
|
|||||||||||

